STR-P004

DRUG3 trials

Sponsors

Starna Therapeutics, Beijing GoBroad Hospital

Conditions

Acute Lymphobkastic LeukemiaAutoimmune DiseasesNon Hodgkin Lymphoma

Early Phase 1

A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

Not yet recruitingNCT07003178

Starna TherapeuticsNon Hodgkin Lymphoma

Start: 2025-06-30End: 2027-05-31Target: 30Updated: 2025-06-04

Unknown Phase

Exploratory Clinical Study on the Safety of STR-P004

RecruitingNCT07143617

Beijing GoBroad HospitalAutoimmune Diseases

Start: 2025-09-16End: 2026-09-14Target: 39Updated: 2026-03-09

To Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of STR-P004

Not yet recruitingNCT07245251

Starna TherapeuticsAcute Lymphobkastic Leukemia

Start: 2025-12-03End: 2026-12-30Target: 11Updated: 2025-11-24

Related Papers

In vivo CD19 CAR T-cell therapy (STR-P004) to induce remission in patients with autoimmune diseases (AID).

Journal of Clinical Oncology2026-05-28